Top Markets
#1 Glidr Glidr +51.75%
#2 Akedo Akedo +50.81%
#3 DOVU DOVU +50.51%
#4 Cross Cross +49.17%
#5 Black Phoenix Black Phoenix +34.33%
#6 Velvet Velvet +32.01%
#7 OVERTAKE OVERTAKE +22.01%
#8 Cap Cap +17.55%
#9 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +16.87%
#10 Movement Movement +13.76%
Coin of the day
Glidr Glidr
Innstillinger
Språk
NORSK
Valuta
USD
Tema
NeuBase Therapeutics, Inc. NeuBase Therapeutics, Inc.

NeuBase Therapeutics, Inc.

NBSE
Rangering i aksjer #39174
Operating as a pre-clinical biopharmaceutical company, NeuBase Therapeutics,... Operating as a pre-clinical biopharmaceutical company, NeuBase Therapeutics, Inc. is dedicated to pioneering therapeutic solutions for rare genetic disorders and various cancers stemming from aberrant genes. At the core of its approach is the proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform. This technology is being utilized to target ailments such as Huntington's disease (HD) and myotonic dystrophy, in addition to a broader spectrum of genetic conditions and applications within oncology. The company's leading therapeutic candidates encompass NT0100, a PATrOL-powered anti-gene therapy for Huntington's disease; NT0200, another PATrOL-enabled anti-gene solution for myotonic dystrophy type 1; and NT0300, a PATrOL-based treatment specifically engineered to address the mutated KRAS gene. NeuBase Therapeutics, Inc. maintains its headquarters in Pittsburgh, Pennsylvania.
Aksjekurs
$0.378
Sist synkronisert: 2024-05-24
Markedsverdi
$618.41K
Endring (1 dag)
0.00%
Endring (1 år)
0.00%
Land
US
Handel NeuBase Therapeutics, Inc. (NBSE)

Kategori

Healthcare
P/B-forhold for NeuBase Therapeutics, Inc. (NBSE)
P/B-forhold per 2026 TTM: 0
Ifølge NeuBase Therapeutics, Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/B-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet et P/B-forhold på 0.
P/B-historikk for NeuBase Therapeutics, Inc. fra 2026 til 2026
P/B-forhold ved hvert års slutt
År P/B-forhold Endre
Ikke nok data for de angitte datoene.
P/B-forhold for lignende selskaper eller konkurrenter
Selskap P/B-forhold Forskjell i P/B-forhold Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.2613 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.3483 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 3.634 -
BE